Global Urothelial Cancer Drugs Market Size, Status and Forecast 2019-2025

Published On: Jun 2019

Format: PDF

Publisher: QY Research

Pages: 92

Report ID: 1545

Urothelial carcinoma or transitional cell carcinoma is a malignant neoplasm occurring from urothelium. The disease is the ninth most common malignancy in the world, with approximately 2.5 million patients and 420,000 newly diagnosed cases each year. Bladder transitional cell carcinoma (TCC) accounted for approximately 90% of all urinary cancer cases.
Market growth is largely attributed to factors such as availability of novel drugs, presence of a strong pipeline, rise in incidence of urothelial cancer due to growing geriatric population, unorganized lifestyle, and rising public awareness.
In 2018, the global Urothelial Cancer Drugs market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Urothelial Cancer Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Urothelial Cancer Drugs development in United States, Europe and China.

The key players covered in this study
Roche
Merck
Bristol-Myers Squibb
AstraZeneca
Pfizer
...

Market segment by Type, the product can be split into
Chemotherapy
Immunotherapy

Market segment by Application, split into
Hospitals
Pharmacy

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Urothelial Cancer Drugs status, future forecast, growth opportunity, key market and key players.
To present the Urothelial Cancer Drugs development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Urothelial Cancer Drugs are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Urothelial Cancer Drugs Market Size Growth Rate by Type (2014-2025)
1.4.2 Chemotherapy
1.4.3 Immunotherapy
1.5 Market by Application
1.5.1 Global Urothelial Cancer Drugs Market Share by Application (2014-2025)
1.5.2 Hospitals
1.5.3 Pharmacy
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Urothelial Cancer Drugs Market Size
2.2 Urothelial Cancer Drugs Growth Trends by Regions
2.2.1 Urothelial Cancer Drugs Market Size by Regions (2014-2025)
2.2.2 Urothelial Cancer Drugs Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 Urothelial Cancer Drugs Market Size by Manufacturers
3.1.1 Global Urothelial Cancer Drugs Revenue by Manufacturers (2014-2019)
3.1.2 Global Urothelial Cancer Drugs Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Urothelial Cancer Drugs Market Concentration Ratio (CR5 and HHI)
3.2 Urothelial Cancer Drugs Key Players Head office and Area Served
3.3 Key Players Urothelial Cancer Drugs Product/Solution/Service
3.4 Date of Enter into Urothelial Cancer Drugs Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Urothelial Cancer Drugs Market Size by Type (2014-2019)
4.2 Global Urothelial Cancer Drugs Market Size by Application (2014-2019)

5 United States
5.1 United States Urothelial Cancer Drugs Market Size (2014-2019)
5.2 Urothelial Cancer Drugs Key Players in United States
5.3 United States Urothelial Cancer Drugs Market Size by Type
5.4 United States Urothelial Cancer Drugs Market Size by Application

6 Europe
6.1 Europe Urothelial Cancer Drugs Market Size (2014-2019)
6.2 Urothelial Cancer Drugs Key Players in Europe
6.3 Europe Urothelial Cancer Drugs Market Size by Type
6.4 Europe Urothelial Cancer Drugs Market Size by Application

7 China
7.1 China Urothelial Cancer Drugs Market Size (2014-2019)
7.2 Urothelial Cancer Drugs Key Players in China
7.3 China Urothelial Cancer Drugs Market Size by Type
7.4 China Urothelial Cancer Drugs Market Size by Application

8 Japan
8.1 Japan Urothelial Cancer Drugs Market Size (2014-2019)
8.2 Urothelial Cancer Drugs Key Players in Japan
8.3 Japan Urothelial Cancer Drugs Market Size by Type
8.4 Japan Urothelial Cancer Drugs Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Urothelial Cancer Drugs Market Size (2014-2019)
9.2 Urothelial Cancer Drugs Key Players in Southeast Asia
9.3 Southeast Asia Urothelial Cancer Drugs Market Size by Type
9.4 Southeast Asia Urothelial Cancer Drugs Market Size by Application

10 India
10.1 India Urothelial Cancer Drugs Market Size (2014-2019)
10.2 Urothelial Cancer Drugs Key Players in India
10.3 India Urothelial Cancer Drugs Market Size by Type
10.4 India Urothelial Cancer Drugs Market Size by Application

11 Central & South America
11.1 Central & South America Urothelial Cancer Drugs Market Size (2014-2019)
11.2 Urothelial Cancer Drugs Key Players in Central & South America
11.3 Central & South America Urothelial Cancer Drugs Market Size by Type
11.4 Central & South America Urothelial Cancer Drugs Market Size by Application

12 International Players Profiles
12.1 Roche
12.1.1 Roche Company Details
12.1.2 Company Description and Business Overview
12.1.3 Urothelial Cancer Drugs Introduction
12.1.4 Roche Revenue in Urothelial Cancer Drugs Business (2014-2019)
12.1.5 Roche Recent Development
12.2 Merck
12.2.1 Merck Company Details
12.2.2 Company Description and Business Overview
12.2.3 Urothelial Cancer Drugs Introduction
12.2.4 Merck Revenue in Urothelial Cancer Drugs Business (2014-2019)
12.2.5 Merck Recent Development
12.3 Bristol-Myers Squibb
12.3.1 Bristol-Myers Squibb Company Details
12.3.2 Company Description and Business Overview
12.3.3 Urothelial Cancer Drugs Introduction
12.3.4 Bristol-Myers Squibb Revenue in Urothelial Cancer Drugs Business (2014-2019)
12.3.5 Bristol-Myers Squibb Recent Development
12.4 AstraZeneca
12.4.1 AstraZeneca Company Details
12.4.2 Company Description and Business Overview
12.4.3 Urothelial Cancer Drugs Introduction
12.4.4 AstraZeneca Revenue in Urothelial Cancer Drugs Business (2014-2019)
12.4.5 AstraZeneca Recent Development
12.5 Pfizer
12.5.1 Pfizer Company Details
12.5.2 Company Description and Business Overview
12.5.3 Urothelial Cancer Drugs Introduction
12.5.4 Pfizer Revenue in Urothelial Cancer Drugs Business (2014-2019)
12.5.5 Pfizer Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details